Verici Dx (LSE:VRCI), the transplant diagnostics company quoted on AIM, is in the spotlight after it published half-year results alongside a proposed new Equity fundraise on 30 September 2026. Trading in its shares was paused from 7.30am on 1 October under AIM's Capital Access Window process while the bookbuild takes place, and the pause is due to last until the outcome of the raise is announced. No result of the fundraise has yet been published.

What the Company Does

Verici Dx develops and sells RNA-based tests designed to help clinicians manage kidney transplant patients. Its lead commercial product, Tutivia, is a blood test for acute rejection after a kidney transplant in the United States, and it runs tests through its own CLIA-certified, CAP-accredited laboratory. Its pipeline includes Protega, which gained an additional American Medical Association CPT PLA code in June 2026, a step the company described as fundamental for commercial reimbursement.

Latest Developments

For the six months to 30 June 2026, Verici Dx reported total Revenue of $1.8m, slightly below the $1.9m recorded a year earlier, as the prior period had included $0.75m of licensing income that was not repeated. Tutivia testing revenue rose 53% to $1.77m. The adjusted EBITDA loss widened to $3.5m from $2.8m, and the operating cash outflow was $3.8m. Cash stood at $2.4m at 30 June, down from $3.3m at the end of 2025.

Commercial traction continued, according to the company. It said 32 transplant centres were onboarded and ordering in the first half, with three more added since 30 June. Together the 35 centres account for 23% of annual US kidney transplants, based on UNOS data cited by Verici, and the average reimbursement rate was $2,300 per test. The company said third-quarter Tutivia orders were on track for a 53% year-on-year increase.

Other news in recent months included a February agreement giving Tutivia in-network status with Blue Cross and Blue Shield of Illinois, New York State clinical laboratory certification in June, and a certified service provider agreement with Olink in August. On 21 September the group said it planned to launch TranscripTx, a transplant-focused genetic test using next-generation sequencing, in the fourth quarter of 2026.

Funding Picture

Verici has relied on regular equity funding. In June 2026 it raised gross proceeds of about £2.6m through a placing and a retail offer, following an oversubscribed raise of around £5.92m in July 2025. The proposed new raise is being run by Singer Capital Markets and Oberon Investments as joint bookrunners, with the price and number of shares to be set after the bookbuild. The company said proceeds would support its commercial team, Marketing and working capital. The company does not pay a dividend.

Sector and index Context

As a member of the FTSE AIM All Share Index, Verici Dx is one of many early-stage healthcare companies on London's junior market whose progress depends on converting clinical validation into reimbursed sales. US payer coverage decisions are a central driver for diagnostic businesses of this kind.

Key Risks

The company remains loss-making with modest cash reserves, so further dilution through equity raises is a recurring risk. Revenue depends on reimbursement from US insurers, continued uptake by transplant centres and competition from other rejection-monitoring technologies. New product launches carry execution risk.

What to Watch Next

The immediate focus is the outcome of the fundraise and the resumption of share trading, including the issue price and amount raised. Beyond that, investors will watch fourth-quarter Tutivia volumes, the TranscripTx launch, additional payer agreements and progress towards reimbursement for Protega. Chief executive Sara Barrington said she was confident momentum would continue into the second half.